[go: up one dir, main page]

BR9915198A - Composto dds e método para medição do mesmo - Google Patents

Composto dds e método para medição do mesmo

Info

Publication number
BR9915198A
BR9915198A BR9915198-7A BR9915198A BR9915198A BR 9915198 A BR9915198 A BR 9915198A BR 9915198 A BR9915198 A BR 9915198A BR 9915198 A BR9915198 A BR 9915198A
Authority
BR
Brazil
Prior art keywords
compound
measuring
dds
alkyladextran
residue
Prior art date
Application number
BR9915198-7A
Other languages
English (en)
Inventor
Hiroshi Susaki
Kazuhiro Inoue
Hiroshi Kuga
Masahiro Ikeda
Yoshinobu Shiose
Hiroshi Korenaga
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of BR9915198A publication Critical patent/BR9915198A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Patente de Invenção: <B>"COMPOSTO DDS E MéTODO PARA MEDIçãO DO MESMO"<D>, caracterizado pelo fato de compreender um composto DDS compreendendo um carboxi (C1-4) alquiladextran poliálcool modificado com um composto sacaride e um resíduo do composto da droga unidos ao carboxi (C1-4) alquiladextran poliálcool, e um método para a medição de um composto DDS no qual um veículo polímero e um resíduo do composto da droga encontram-se ligados um ao outro por meio de um espaçador compreendendo de 2 a 8 amino ácidos ligados por ligação/ligações de peptídeo, o qual compreende as etapas de tratamento do composto DDS com um peptidase, e a medição do hidrolisato resultante.
BR9915198-7A 1998-10-30 1999-10-29 Composto dds e método para medição do mesmo BR9915198A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP31013098 1998-10-30
JP32927298 1998-11-19
PCT/JP1999/006016 WO2000025825A1 (en) 1998-10-30 1999-10-29 Dds compounds and method for assaying the same

Publications (1)

Publication Number Publication Date
BR9915198A true BR9915198A (pt) 2001-08-14

Family

ID=26566202

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915198-7A BR9915198A (pt) 1998-10-30 1999-10-29 Composto dds e método para medição do mesmo

Country Status (15)

Country Link
US (2) US6811996B1 (pt)
EP (2) EP1619210A1 (pt)
KR (1) KR20010090602A (pt)
CN (2) CN1191093C (pt)
AU (1) AU765409B2 (pt)
BR (1) BR9915198A (pt)
CA (1) CA2348931A1 (pt)
EA (1) EA003790B1 (pt)
HK (1) HK1042438A1 (pt)
ID (1) ID29943A (pt)
IL (1) IL142842A0 (pt)
MX (1) MXPA01004239A (pt)
NO (1) NO20012128L (pt)
TW (1) TWI232930B (pt)
WO (1) WO2000025825A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
EP1080732A4 (en) * 1998-05-22 2004-08-25 Daiichi Seiyaku Co DRUG COMPOSITION
AU765409B2 (en) * 1998-10-30 2003-09-18 Daiichi Pharmaceutical Co., Ltd. DDS compounds and method for assaying the same
CA2412582A1 (en) * 2000-06-29 2002-01-03 Daiichi Pharmaceutical Co., Ltd. Dds compound and process for the preparation thereof
US7569556B2 (en) * 2004-05-10 2009-08-04 Board Of Trustees Of Michigan State University Method of use of carboxylated polysaccharides topically on the eyeball
US9820986B2 (en) * 2005-03-04 2017-11-21 Taiwan Hopaz Chems, Mfg. Co., Ltd. Glycopeptide compositions
CA2625426A1 (en) * 2005-09-22 2007-03-29 Hadasit Medical Research Services & Development Limited Dextran and arabinogalactan conjugates of therapeutically active compounds
CN1973902B (zh) * 2006-12-12 2010-11-10 东北师范大学 以人参多糖为载体的抗肿瘤药物阿霉素复合物及制备方法
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
CN107141410B (zh) 2010-05-25 2022-12-09 辛德弗雷克斯公司 聚合物缀合的MetAP2抑制剂及其应用的治疗方法
TW201348244A (zh) * 2012-05-23 2013-12-01 Iner Aec Executive Yuan 醣質藥物造影劑前驅物之合成方法
CN115960111A (zh) * 2012-10-11 2023-04-14 第一三共株式会社 抗体－药物偶联物
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
US9173956B2 (en) 2013-04-10 2015-11-03 Syndevrx, Inc. METAP2 inhibitors and methods of treating obesity
JP6130517B2 (ja) 2013-12-25 2017-05-17 第一三共株式会社 抗ｔｒｏｐ２抗体−薬物コンジュゲート
PL4212552T3 (pl) 2014-01-31 2025-03-17 Daiichi Sankyo Company, Limited Koniugat przeciwciało anty-her2-lek
SI3129063T1 (sl) 2014-04-10 2021-08-31 Daiichi Sankyo Company PROTI-HER3 konjugat zdravila s protitelescem
ES2754348T3 (es) 2014-04-10 2020-04-17 Daiichi Sankyo Co Ltd Conjugado de (anticuerpo anti-HER2)-fármaco
IL290959B2 (en) 2015-06-29 2023-04-01 Daiichi Sankyo Co Ltd Preparations containing antibody-drug conjugates and methods for their production
ES2893749T3 (es) 2015-12-10 2022-02-10 Syndevrx Inc Derivados de fumagilol y polimorfos de los mismos
JP7022066B2 (ja) 2016-01-11 2022-02-17 シンデブルックス，インコーポレイティド 代謝機能不全によって引き起こされる腫瘍の治療
TWI842117B (zh) * 2016-03-07 2024-05-11 美商愛羅海德製藥公司 治療性化合物之標靶性配體
KR102403408B1 (ko) 2016-09-02 2022-05-30 애로우헤드 파마슈티컬스 인코포레이티드 표적화 리간드
BR112019005247A2 (pt) 2016-10-07 2019-06-04 Daiichi Sankyo Co Ltd terapia para o câncer resistente a fármacos por meio de administração de conjugado de anticorpo anti-her2/fármaco
TW202508642A (zh) 2016-12-12 2025-03-01 日商第一三共股份有限公司 抗體-藥物結合物與免疫檢查點抑制劑之組合、以及醫藥組成物之用途
TWI780104B (zh) 2017-01-17 2022-10-11 日商第一三共股份有限公司 抗ｇｐｒ２０抗體及抗ｇｐｒ２０抗體-藥物結合物、以及其製造方法及用途
TW202530219A (zh) 2017-05-15 2025-08-01 日商第一三共股份有限公司 抗體－藥物結合物之製造方法
CN117838881A (zh) 2017-08-31 2024-04-09 第一三共株式会社 制备抗体-药物缀合物的新方法
EP3677589B1 (en) 2017-08-31 2025-11-26 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
BR112020023373A2 (pt) 2018-05-18 2021-02-09 Daiichi Sankyo Company, Limited conjugado, composição, e, uso de um conjugado ou de uma composição
TWI846717B (zh) 2018-07-27 2024-07-01 日商第一三共股份有限公司 辨識抗體-藥物結合物之藥物部位的蛋白質
SG11202100947SA (en) 2018-07-31 2021-03-30 Daiichi Sankyo Co Ltd Treatment of metastatic brain tumor by administration of antibody-drug conjugate
JP2022512826A (ja) 2018-10-26 2022-02-07 シンデブルックス，インコーポレイティド ＭｅｔＡＰ２阻害剤のバイオマーカーとその応用
PH12022550039A1 (en) 2019-07-10 2023-06-26 Cybrexa 3 Inc Peptide conjugates of cytotoxins as therapeutics
MX2022000450A (es) 2019-07-10 2022-04-25 Cybrexa 3 Inc Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos.
WO2024104186A1 (zh) * 2022-11-17 2024-05-23 菲鹏生物股份有限公司 化合物及其制备方法和封闭剂

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386026A (en) * 1981-04-20 1983-05-31 Merck & Co., Inc. Cell-specific glycopeptide ligands
JP2791001B2 (ja) 1990-02-16 1998-08-27 株式会社ディ・ディ・エス研究所 グリコシル−蛋白誘導体
JPH0784481B2 (ja) 1991-02-21 1995-09-13 株式会社デイ・デイ・エス研究所 カルボキシメチルマンノグルカン及びその誘導体
JP2589431B2 (ja) 1991-05-13 1997-03-12 株式会社ディ・ディ・エス研究所 糖修飾ポリグルタミン酸誘導体及びその製造法
JP2774417B2 (ja) 1991-08-07 1998-07-09 株式会社ディ・ディ・エス研究所 ペプチド骨格を有する分枝鎖型糖複合体及び微粒子キャリヤー
JP2589435B2 (ja) 1991-09-17 1997-03-12 株式会社ディ・ディ・エス研究所 糖修飾ポリリジン誘導体
JP2774429B2 (ja) 1992-03-17 1998-07-09 株式会社ディ・ディ・エス研究所 糖骨格を有する分枝鎖型誘導体
JP3359955B2 (ja) * 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
EP0640622B1 (en) * 1993-02-26 2000-08-09 Drug Delivery System Institute, Ltd. Polysaccharide derivative and drug carrier
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JPH0784481A (ja) 1993-06-26 1995-03-31 Ricoh Co Ltd 画像形成装置
GB2282384B8 (en) * 1993-08-18 1997-09-04 Europ Economic Community Drug delivery agents incorporating mitomycin
JP3418693B2 (ja) 1993-09-06 2003-06-23 敏宏 赤池 ポリ−ε−置換−Ｌ−リジンのＤ−ガラクトピラノシル−グルコン酸誘導体
JPH07228688A (ja) 1994-02-18 1995-08-29 Yamanouchi Pharmaceut Co Ltd 糖修飾ポリ−ω−置換−Ｌ−グルタミン酸誘導体およびその製造方法
DE69530553T2 (de) * 1994-05-13 2004-03-25 KURARAY CO., LTD, Kurashiki Medizinisches polymergel
JP3001381B2 (ja) 1994-09-16 2000-01-24 株式会社ディ・ディ・エス研究所 臓器移行性を有する多糖誘導体および薬物担体
US5886143A (en) * 1994-12-07 1999-03-23 Neorx Corporation Hepatic-directed compounds and reagents for preparation thereof
JP3053764B2 (ja) * 1995-03-17 2000-06-19 財団法人神奈川科学技術アカデミー 糖鎖高分子及びそれを用いた細胞処理剤並びに処理方法
US5714511A (en) * 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
US6368598B1 (en) * 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
EP0941120A4 (en) * 1996-11-05 2004-08-18 Bristol Myers Squibb Co BRANCHED PEPTIDLINKERS
US6340461B1 (en) * 1996-12-17 2002-01-22 David Stephen Terman Superantigen based methods and compositions for treatment of diseases
US6338843B1 (en) 1997-06-12 2002-01-15 Ml Laboratories Biologically active materials
EP1080732A4 (en) * 1998-05-22 2004-08-25 Daiichi Seiyaku Co DRUG COMPOSITION
AU765409B2 (en) * 1998-10-30 2003-09-18 Daiichi Pharmaceutical Co., Ltd. DDS compounds and method for assaying the same

Also Published As

Publication number Publication date
MXPA01004239A (es) 2002-06-04
IL142842A0 (en) 2002-03-10
CN1661044A (zh) 2005-08-31
AU765409B2 (en) 2003-09-18
US20040192644A1 (en) 2004-09-30
EA200100485A1 (ru) 2001-12-24
NO20012128L (no) 2001-06-20
WO2000025825A1 (en) 2000-05-11
KR20010090602A (ko) 2001-10-18
EA003790B1 (ru) 2003-10-30
CA2348931A1 (en) 2000-05-11
US6811996B1 (en) 2004-11-02
US7041818B2 (en) 2006-05-09
HK1042438A1 (zh) 2002-08-16
EP1155702A4 (en) 2004-12-15
ID29943A (id) 2001-10-25
CN1332640A (zh) 2002-01-23
EP1619210A1 (en) 2006-01-25
CN1191093C (zh) 2005-03-02
AU6488099A (en) 2000-05-22
TWI232930B (en) 2005-05-21
EP1155702A1 (en) 2001-11-21
NO20012128D0 (no) 2001-04-30

Similar Documents

Publication Publication Date Title
BR9915198A (pt) Composto dds e método para medição do mesmo
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
WO2001005950A3 (en) Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
ATE249209T1 (de) Arzneistoffträgerpartikel für die gewebespezifische arzneistoffapplikation
PT662827E (pt) Metodos de diagnostico e composicoes farmaceuticas a base de proteinas notch e acidos nucleicos
DE50014571D1 (de) Träger-pharmaka-konjugate
DK1105409T3 (da) Beskyttelse af endogene terapeutiske peptider fra peptidaseaktivitet ved konjugering med blodkomponenter
TR200002869T2 (tr) İkame edilmiş indolealkonik asitler.
ID21045A (id) Asam amino termodifikasi, obat-obatan yang mengandung senyawa ini dan proses pembuatannya
CY1112330T1 (el) Πρωτεϊνες συνδεσης gag
HUP0001138A3 (en) Amino acids containing benzodioxane or benzoxazine, pharmaceutical compositions thereof and process for producing the same
ATE394484T1 (de) Smad 6 und dessen anwendungen
AU2154801A (en) Method for linking molecular substances
DE69828394D1 (de) Pharmazeutische zusammensetzung mit lyophilisierten lyposomen welche einen unlöslichen aktiven wirkstoff einschliessen, verfahren zu dessen herstellung
CY1105452T1 (el) Παραγωγα της κυκλοσπορινης και μεθοδος παρασκευης των εν λογω παραγωγων
DE68925275D1 (de) Endotoxin-bindeprotein und dessen verwendung
ATE193022T1 (de) Heparin-und sulfatid-bindende peptide vom typ 1 der wiederkehrenden sequenzen vom menschlichen thrombospondin
CY1108288T1 (el) Αντισωματα για το αντιγονο κυτταρων langerhans θηλαστικων και χρησεις τους
DE69704269D1 (de) Dendritische, lysinhaltige Polypeptide zur gezielten Arzneimittelabreichung
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
DK0845034T3 (da) Peptid med pronociceptive egenskaber
NO942930D0 (no) Forbindelser og produkter basert på Amadori-reaksjoner samt fremgangsmåte til fremstilling av bruk av samme
ATE332916T1 (de) Farbstoff-markiertes peptid und dessen verwendung zur diagnostik
DK0769025T3 (da) Metoder og sammensætninger i relation til proteoglycanproteiner til diagnosticering af brusknedbrydning
ID17348A (id) 1-naftoilguanidin tersubstitusi, proses untuk pembuatannya, pemakaiannya sebagai obat atau diagnostik, dan obat yang mengandungnya

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE ACORDO COM ART. 8O, 11, 13, E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/4745 (2006.01), A61K 47/61 (2017.0